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male rats, but deteriorated withdrawal in females. Neither sex steroid hor-
mones, nor phytoestrogens changed metamizol analgesic action. Mosaic
immunohistochemical effects were revealed.
Conclusion: Increasing pain sensitivity estradiol and phytoestrogens did
not decrease metamizol and morphine analgesia. Data show that fluctua-




SYNERGISTIC ANALGESIC INTERACTION BETWEEN
MORPHINE AND BIM-46187
M. Auguet C. Favre-Guilmard °, H. Zeroual-Hider, G. Prevost,
P.E. Chabrier. IPSEN, Institut Henri Beaufour, Les Ulis, France
BIM-46187 is a new anticancer agent that acts as a modulator of the
heterotrimeric G protein complex. Considering that opioids are second
and third-line of choice for the pain management of tumor patients and
that opioid receptors belong to the large superfamily of G protein-coupled
receptors, the possible interaction of BIM-46187 on the analgesic effects of
morphine has been studied in experimental models of pain. The interaction
between BIM-46187 (i.v.) and morphine (i.p.) was evaluated by isobolo-
graphic analysis of analgesia in the carrageenan-induced hyperalgesia
(ED50 = 0.42 and 0.61mg/kg for BIM-46187 and morphine, respectively)
and the chronic constriction injury (ED50 = 2.5 and 1.4mg/kg for BIM-
46187 and morphine, respectively) models in rats. In both models the
co treatment with the compounds (ratio 1/1) resulted in a synergistic
analgesic effect and resulted in a reduction by at least 20 fold in the dose
of morphine. In contrast, the co treatment of BIM-46187 and morphine up
to 3mg/kg of each compound did not increase side effect assessed in the
rotarod test in rats. A positive interaction on the analgesic effects was also
observed in the model of carrageenan induced hyperalgesia when BIM-
46187 was associated with fentanyl, another opioid agonist structurally
unrelated to morphine. In conclusion, the opioid sparing effect resulting
from the synergy observed with the co treatment of BIM-46187 may be
clinically relevant during the management of cancer.
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THE NEW ANTICANCER AGENT BIM-46187 ELICITS
ANALGESIC PROPERTIES
C. Favre-Guilmard, H. Zeroual-Hider, C. Soulard, G. Prevost,
P.E. Chabrier, M. Auguet °. IPSEN, Institut Henri Beaufour, Les Ulis,
France
BIM-46187 is a new modulator of the heterotrimeric G protein complex,
a potential new target in cancer therapy. Cancer is associated to pain
syndromes resulting from direct tumour involvement or from cancer-
directed therapy. Considering that many mediators of pain act through
G protein coupled receptors, the effects of intravenous administration of
BIM-46187 were evaluated on different experimental models of pain.
BIM-46187 elicited a dose dependent analgesic effect in the models
of carrageenan-induced hyperalgesia (ED50 = 0.42mg/kg) and of chronic
constriction injury (ED50 = 2.5mg/kg) in rats. Moreover, BIM-46187
(3mg/kg; i.v.) was also effective in the model of neuropathy induced
by taxol in rats. BIM-46187 up to 10mg/kg modified neither the paw
oedema induced by carrageenan nor the motor performance assessed by
the rotarod test in rats. In mice, BIM-46187 up to 10mg/kg was ineffective
in the hot plate test suggesting a lack of effect on acute nociception.
These results indicate that, unlike other anticancer agents, BIM-46187
possesses analgesic properties and suggest that this effect is due to
peripheral action. This property may be beneficial during therapeutic use
in oncology especially if BIM-46187 is associated with other anticancer
agents inducing neuropathy.
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INVOLVEMENT OF CONNECTIONS BETWEEN THE
ANTERIOR PRETECTAL NUCLEUS AND THE DEEP LAYERS
OF THE SUPERIOR COLLICULUS IN ANTINOCICEPTIVE
PROCESSES
A.D. Carvalho, D.H. Elias-Filho, N.C. Coimbra°. Department of
Pharmacology, School of Medicine of Ribeirão Preto of the University of
São Paulo (FMRP-USP), Ribeirão Preto (SP), Brazil
The aim of this work was to study the physiological role of anterior
pretectal nucleus (APtN) and the superior colliculus (SC) neural con-
nections in the antinociception evoked by APtN electrical stimulation.
Wistar rats (n-8, per group), weighing 200–250 g, were anaesthetized with
sodium pentobarbital (45mg/kg, IP) and submitted to a stereotaxic surgery
for the introduction of guide-cannula glued to a brain electrode aiming
at the NPtA and a guide-cannula aiming at the SC. After 5 days of
post-operative recovery, the tail-flick baseline was recorded, and the tail-
withdrawal latency (TFL) was measured again at 0, 15, 30, 45 e 60 min
after the electrical stimulation (100muA; 15 s) of the APtN. After 24 h,
5.0mug/0.5muL of methysergide, naloxonazine or physiological saline,
or ibotenc acid (1.0mug/0.5muL; under anesthesia) were microinjected
into the SC, in independent groups of animals and, 10 min after the
pharmacological antagonism with methysergide, 24h after naloxonazine
administration or 5 days after the neurochemical damage in the SC, the
APtN was electrically stimulated, following the TFL recording. The elec-
trical stimulation of APtN caused a statistically significant antinociception
with 60 min of duration. This antinociceptive phenomenon decreased after
the neurochemical damage of the CS. Both methysergide and naloxonazine
microinjected into the intermediate and deep layers of the superior col-
liculus antagonized the APtN-electric stimulation-induced antinociception.
These findings suggest that SC neural substrates, as well as mu1-opioid
receptor and serotonergic receptors exert a key-role in the APtN-electric
stimulation-induced antinociception.
This work was supported by CNPq, FAPESP and FAEPA.
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PLACEBO EFFECTS IN LASER-EVOKED PAIN POTENTIALS
D. Matre1 °, T.D. Wager2, K.L. Casey3,4. 1Dept. of Occupational
Musculoskeletal Disorders, National Institute of Occupational Health,
Oslo, Norway, 2Dept. of Psychology, Columbia University, New York, NY,
3Neurology Research Lab, VA Medical Center, Ann Arbor, MI, 4Dept. of
Neurology, University of Michigan, Ann Arbor, MI, USA
Background and Aims: Placebo treatment may affect multiple com-
ponents of pain, including inhibition of nociceptive input, automatic or
deliberative appraisal of pain, or cognitive judgments involved in pain
reporting. If placebo analgesia is due in part to an attenuation of early
nociceptive processing, then pain-evoked event-related potentials (ERPs)
should be reduced with placebo. In this study we tested for placebo effects
in P2 laser-evoked potentials at midline scalp electrodes.
Methods: Twenty-four subjects participated in the study. Subjects received
painful laser stimuli (1-ms; Thulium YAG infrared laser) on the volar
forearm. ERPs were recorded from midline electrodes (FCz, Cz, CPz, Pz).
The amplitude of the first major negative (N2) and positive (P2) component
was extracted and compared between areas treated with a placebo analgesic
cream and a control cream. In reality both creams were ineffective. The
treatments differed only in the instructions about expected analgesia given
to participants.
Results: We found that placebo treatment produced significant decreases
in P2 amplitude, and that P2 placebo responses were large enough to reflect
a meaningful difference in nociceptive processing. However, we also found
evidence that the very robust placebo-induced decreases in reported pain
are not solely explained by early reductions in P2. N2 amplitude was
affected by neither placebo nor reduction of laser intensity.
Conclusions: These results suggest that placebo treatment affects early
nociceptive processing, but that another component of placebo effects in
reported pain occurs later, either in retrospective evaluation of pain or
cognitive judgments about pain reports.
